Literature DB >> 12164690

Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

Raja B Khan1, Weiji Shi, Howard T Thaler, Lisa M DeAngelis, Lauren E Abrey.   

Abstract

Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12164690     DOI： 10.1023/a:1016077907952

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  11 in total

1.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors:  L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

3.  Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.

Authors:  G Vassal; D Valteau; M Bonnay; C Patte; F Aubier; J Lemerle
Journal:  Pediatr Hematol Oncol       Date:  1990       Impact factor: 1.969

4.  Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.

Authors:  L Recht; D J Straus; C Cirrincione; H T Thaler; J B Posner
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

5.  Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.

Authors:  S Hiraga; N Arita; T Ohnishi; E Kohmura; K Yamamoto; Y Oku; T Taki; M Sato; K Aozasa; T Yoshimine
Journal:  J Neurosurg       Date:  1999-08       Impact factor: 5.115

6.  Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.

Authors:  N Guha-Thakurta; D Damek; C Pollack; F H Hochberg
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

7.  Treatment for primary CNS lymphoma: the next step.

Authors:  L E Abrey; J Yahalom; L M DeAngelis
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

8.  Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.

Authors:  W E Evans; P R Hutson; C F Stewart; D A Cairnes; W P Bowman; G Rivera; W R Crom
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

9.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

10.  Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications.

Authors:  C Balmaceda; J J Gaynor; M Sun; J T Gluck; L M DeAngelis
Journal:  Ann Neurol       Date:  1995-08       Impact factor: 10.422
View more
  42 in total

Review 1.  Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.

Authors:  Chi-Chao Chan; James L Rubenstein; Sarah E Coupland; Janet L Davis; J William Harbour; Patrick B Johnston; Nathalie Cassoux; Valerie Touitou; Justine R Smith; Tracy T Batchelor; Jose S Pulido
Journal:  Oncologist       Date:  2011-11-01

2.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.

Authors:  Dana J Wallace; DeFen Shen; George F Reed; Masaru Miyanaga; Manabu Mochizuki; H Nida Sen; Samuel S Dahr; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 4.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Prophylactic intrathecal chemotherapy in primary CNS lymphoma.

Authors:  Monica Sierra Del Rio; Damien Ricard; Caroline Houillier; Soledad Navarro; Alberto Gonzalez-Aguilar; Ahmed Idbaih; Gentian Kaloshi; Soufiane Elhallani; Antonio Omuro; Sylvain Choquet; Carole Soussain; Khé Hoang-Xuan
Journal:  J Neurooncol       Date:  2011-07-08       Impact factor: 4.130

Review 6.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

7.  Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.

Authors:  Samir Dalia; Peter Forsyth; Julio Chavez; Samantha Price; Bijal Shah; Celeste Bello; Lubomir Sokol; Edward Pan; Eduardo Sotomayor; Ji-Hyun Lee; Kate Fisher; Michael Jaglal
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

8.  Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.

Authors:  Tobias Birnbaum; Katja Bochmann; Louisa von Baumgarten; Andreas Straube
Journal:  J Neurooncol       Date:  2013-01-17       Impact factor: 4.130

9.  Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Authors:  Elisa J Pulczynski; Outi Kuittinen; Martin Erlanson; Hans Hagberg; Alexander Fosså; Mikael Eriksson; Marie Nordstrøm; Bjørn Østenstad; Øystein Fluge; Sirpa Leppä; Bente Fiirgaard; Hanne Bersvendsen; Unn-Merete Fagerli
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

10.  Primary central nervous system lymphoma.

Authors:  Stephane Doucet; Priya Kumthekar; Jeffrey Raizer
Journal:  Curr Treat Options Oncol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.